Response,Percentage of drugs approved in 2019
Met PDUFA goal date*,100%
First cycle of review,90%
Approved in the United States before receiving approval in any other country,69%
Priority review,58%
Drugs for orphan diseases,44%
First-in-class,42%
Fast Track,35%
Breakthrough therapy,27%
Accelerated Approval program,19%
